Miyoung Kim

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations

Lux-lung 6, Medicine, Randomised Phase 3 +8

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.1K citations

Oncology, Phase 2B, Pathology +8

Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020

Young-Joon Park, Young June Choe, Ok Park et al. · Emerging infectious diseases · 2020 · 539 citations · Full text

Infectious Disease Epidemiology, Contact Tracing, Index Patients +15

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak et al. · The Lancet Respiratory Medicine · 2019 · 164 citations

Placebo-controlled Phase 3, Pleural Disease, Anti-cancer Agent +6

EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes

Kwi-Sook Choi, Hwoon‐Yong Jung, Kee Don Choi et al. · Gastrointestinal Endoscopy · 2011 · 144 citations

Surgical Oncology, Emr Versus Gastrectomy, Gastrointestinal Oncology +8